Literature DB >> 14529833

Phenotype correction of Fanconi anemia group A hematopoietic stem cells using lentiviral vector.

Kaoru Yamada1, Ali Ramezani, Robert G Hawley, Wolfram Ebell, Fre Arwert, Larry W Arnold, Christopher E Walsh.   

Abstract

Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure due to defective stem cell function. FA patients' cells are hypersensitive to DNA cross-linking agents such as mitomycin C (MMC), exposure to which results in cytogenetic aberrations and cell death. To date Moloney murine leukemia virus vectors have been used in clinical gene therapy. Recently, third-generation lentiviral vectors based on the HIV-1 genome have been developed for efficient gene transfer to hematopoietic stem cells. We generated a self-inactivating lentiviral vector expressing the FA group A cDNA driven by the murine stem cell virus U3 LTR promoter and used the vector to transduce side-population (SP) cells isolated from bone marrow of Fanconi anemia group A (Fanca) knockout mice. One thousand transduced SP cells reconstituted the bone marrow of sublethally irradiated Fanca recipient mice. Phenotype correction was demonstrated by stable hematopoiesis following MMC challenge. Using real-time PCR, one proviral vector DNA copy per cell was detected in all lineage-committed cells in the peripheral blood of both primary and secondary recipients. Our results suggest that the lentiviral vector transduces stem cells capable of self-renewal and long-term hematopoiesis in vivo and is potentially useful for clinical gene therapy of FA hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529833     DOI: 10.1016/s1525-0016(03)00223-5

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  9 in total

Review 1.  Survival of the fittest: in vivo selection and stem cell gene therapy.

Authors:  Tobias Neff; Brian C Beard; Hans-Peter Kiem
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

Review 2.  Topics in pediatric leukemia--Fanconi's anemia: new insights.

Authors:  Noah Federman; Kathleen M Sakamoto
Journal:  MedGenMed       Date:  2005-04-06

Review 3.  Mouse models of Fanconi anemia.

Authors:  Kalindi Parmar; Alan D'Andrea; Laura J Niedernhofer
Journal:  Mutat Res       Date:  2009-04-10       Impact factor: 2.433

4.  Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.

Authors:  P S Becker; J A Taylor; G D Trobridge; X Zhao; B C Beard; S Chien; J Adair; D B Kohn; J E Wagner; A Shimamura; H-P Kiem
Journal:  Gene Ther       Date:  2010-05-20       Impact factor: 5.250

Review 5.  Fanconi anemia.

Authors:  Allison M Green; Gary M Kupfer
Journal:  Hematol Oncol Clin North Am       Date:  2009-04       Impact factor: 3.722

Review 6.  Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia.

Authors:  Lars U W Müller; David A Williams
Journal:  Mutat Res       Date:  2009-04-02       Impact factor: 2.433

7.  Correction of Fanconi Anemia Group C Hematopoietic Stem Cells Following Intrafemoral Gene Transfer.

Authors:  Ouassila Habi; Johanne Girard; Valérie Bourdages; Marie-Chantal Delisle; Madeleine Carreau
Journal:  Anemia       Date:  2010

8.  Disrupted Signaling through the Fanconi Anemia Pathway Leads to Dysfunctional Hematopoietic Stem Cell Biology: Underlying Mechanisms and Potential Therapeutic Strategies.

Authors:  Anja Geiselhart; Amelie Lier; Dagmar Walter; Michael D Milsom
Journal:  Anemia       Date:  2012-05-23

Review 9.  The Fanconi anemia pathway and ubiquitin.

Authors:  Céline Jacquemont; Toshiyasu Taniguchi
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.